CPA Participates in 3rd China Pharma, Biotech & Chemical IP Forum
During 25-27 May 2012, the 3rd China Pharma, Biotech & Chemical Intellectual Property Forum was held in Taizhou, China. The forum was co-organized by the Chinese-American Chemical Society, American Chemical Society, China Intellectual Property Society, Chinese Pharmaceutical Association, and Intellectual Property Office of Jiangsu Province.
This year’s forum, with a theme of “R&D IP Protection, Innovation Transfer and Commercialization”, drew more than 300 attendants, including officials of patent offices from home and abroad, court judges, IP experts and academicians, as well as representatives from healthcare and chemical multinational companies, contract research organizations (CRO), international law firms, and major domestic patent agencies.
China Patent Agent (H.K.) Ltd. (CPA) was represented in the forum by the firm’s deputy general managers Mr. Zeng Xiangling and Ms. Tina Tai, its Shanghai office director Mr. Liu Dong, and patent attorney Ms. Liu Xin.
Deputy general manager Mr. Zeng moderated the forum session on “Invention and Patent Strategies”, during which patent examination officials from the four major patent offices, namely, State Intellectual Property Office (SIPO), US Patent and Trademark Office (USPTO), European Patent Office (EPO) and Japan Patent Office (JPO), presented the characteristics and compared the similarities and differences of their respective countries in patent examination with respect to pharma and biotech inventions.
In the panel presentation on “Patent Prosecution and IP Protection”, deputy general manager Ms. Tina Tai spoke about the requirement on disclosure of experimental data for pharma patents in examination practice. She also advised on drafting strategies to avoid objection with particular attention to experimental data for pharma patents, as well as reviewed the firm’s successful case concerning data disclosure related dispute, and proposed how to overcome rejection based on lack of data.
CPA deputy general manager Mr. Zeng Xiangling moderating the forum discussion on "Invention and Patent Strategies"
CPA deputy general manager Ms. Tina Tai presenting on the topic of data disclosure requirements for pharma patents
